Navigation Links
Orexigen® Therapeutics Provides a Regulatory Update on Contrave® NDA
Date:6/3/2011

SAN DIEGO, June 3, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced today that it recently met with the Food and Drug Administration (FDA) regarding the New Drug Application for Contrave® (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss.  Orexigen sought the meeting to gain clarity on the approval deficiency stated in the Complete Response letter the Company received on January 31, 2011.  The Complete Response letter requested that the Company conduct a randomized, double-blind, placebo-controlled trial of sufficient size and duration to demonstrate that the risk of major adverse cardiovascular events in overweight and obese subjects treated with Contrave does not adversely affect the drug's benefit-risk profile.  

Orexigen submitted a specific proposal to address the theoretical cardiovascular risk cited in the approval deficiency and also explored approval for a narrowed indication in patients with lower cardiovascular risk until data from the proposed outcomes trial could be reviewed for label expansion.  The Division of Metabolic and Endocrinologic Products (DMEP) advised Orexigen that the proposed cardiovascular outcomes trial would not adequately address the approval deficiency and instead, requested a pre-approval cardiovascular outcomes trial that Orexigen believes is unprecedented and would generate significantly more information than is necessary or feasible.  Additionally, DMEP stated that it would not consider approving Contrave for a narrowed population without first reviewing data from a cardiovascular outcomes trial.  Finally, DMEP said that it intends to hold a general advisory committee early next year to discuss cardiovascular assessment for obesity therapeutics, and that any agreement reached on the desi
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
7. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
11. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Alexza Pharmaceuticals, Inc. ... is participating in two healthcare conferences during the third ... the Morgan Stanley Global Healthcare 2014 Conference.  Alexza,s corporate ... Conference.  The details on each event are below: ... August 11, 2014 in Boston , ...
(Date:7/29/2014)... 2014 Edwards Lifesciences Corporation (NYSE: EW ... and hemodynamic monitoring, today reported net income for the quarter ... diluted share, and non-GAAP net income of $94.0 million, or ... a year earlier was $93.3 million, or $0.81 per diluted ... per diluted share.  Net sales for the ...
(Date:7/29/2014)... , July 29, 2014 New high priced ... Part D by a projected $2.9 to $5.8 billion ... actuarial firm Milliman released today by the Pharmaceutical Care ... premiums could increase by as much as 8.6 percent ... drugs, including Sovaldi and Olysio. The study ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
... 2012  BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today ... present a company update at the J.P. Morgan Healthcare Conference ... a.m. PT.  Interested parties may access a ... section of the BioMarin website, www.BMRN.com .  A replay ...
... UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") ... Balance Sheet over the last twelve months, as referenced ... the Year ended September 30, 2011. In the report ... notes and accounts payable, decreased to $284,636, a 59% ...
Cached Medicine Technology:BioMarin to Present at the J.P. Morgan Healthcare Conference 2UV Flu Technologies Aggressively Paying Down Debt to Build Platform for Expected Growth in Consumer and Hospital Markets 2UV Flu Technologies Aggressively Paying Down Debt to Build Platform for Expected Growth in Consumer and Hospital Markets 3
(Date:7/30/2014)... July 30, 2014 The Hearing Aid ... five years to 2014. Following a multiyear drop during ... demographic trends, the expansion of private healthcare coverage and, ... that Hearing Aid Clinics industry revenue will ... billion during the five years to 2014. , According ...
(Date:7/30/2014)... in every twenty elderly American adults is being financially ... burgeoning public health crisis especially affects poor and black ... researchers, and any citizen who cares about the dignity ... of Weill Cornell Medical College in the US. She ... elder abuse, the findings of which appear in the ...
(Date:7/30/2014)... tests could be created to diagnose diseases such as ... to earlier intervention, according to new findings from the ... the components of memory using a combination of tests ... to create a diagnostic tool for distinguishing between different ... of amnesia caused by head trauma. , Dr ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The global ... billion by 2020, according to a new study by ... procedures and the growing prevalence of diabetes, obesity and ... the forecast period. In addition, the introduction of technologically ... penetration of minimally invasive procedures in emerging Asian markets ...
(Date:7/30/2014)... TX (PRWEB) July 30, 2014 ... Louisiana Attorney General’s Office against the maker of ... alleges that Fresenius Medical Care defrauded the state, ... these products, called dialysates, before they were recalled ... complaints related to these products pending in the ...
Breaking Medicine News(10 mins):Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Older adults are at risk of financial abuse 2Health News:Hope for more accurate diagnosis of memory problems 2Health News:Global Catheters Market - Industry Size, Trends, Analysis, Growth, Players, Outlook and Forecast Research Report from 2014 to 2020: Grand View Research, Inc 2Health News:Global Catheters Market - Industry Size, Trends, Analysis, Growth, Players, Outlook and Forecast Research Report from 2014 to 2020: Grand View Research, Inc 3Health News:Louisiana Attorney General Files Complaint Against GranuFlo Manufacturer, Baron and Budd Reports 2Health News:Louisiana Attorney General Files Complaint Against GranuFlo Manufacturer, Baron and Budd Reports 3
... post-traumatic stress disorder show reduced pain sensitivity, a pattern ... the brain, according to a report. ,Post-traumatic stress ... in individuals exposed to a traumatic event. It is ... avoidance of stimuli related to the event, according to ...
... pharma major Ranbaxy Laboratories Limited has received the approval ... manufacture and market generic hypertension drug Atenolol in the ... of 25 mg, 50 mg, and 100 mg dosage ... the first quarter of 2007, the company said in ...
... woman has brought about a revolution in the lives of ... retiree from Hong Kong, decided one day to live in ... That momentous decision has made a huge difference to hundreds ... the only nurse at the Tanshan Leper Rehabilitation Village in ...
... from over in Bihar, which recorded 51 new cases in 2006.// ... in the state even though millions were spent on a series ... put the figure of polio cases at over 60. ... detected in Kishanganj, Purnea, East Champaran and Sitamarhi districts. ...
... in the Archives of Pediatrics & Adolescent Medicine, one of ... vitamin// and mineral supplement while pregnant may be less likely ... have babies weighing less than 2,500 grams, and their newborns ... seven days of life. ,Low birth weight, or ...
... widely held belief that cutting down on calories could ... acquired added meaning.// Researchers from University of Alabama at ... risk of cancer is the body composition (being lean ... instead of consumed, which mounts the risk of cancer., ...
Cached Medicine News:Health News:Patients With PTSD Experience Less Pain Sensitivity 2Health News:A ‘Good Samaritan’ to the Aid of Lepe 2Health News:A ‘Good Samaritan’ to the Aid of Lepe 3Health News:Multivitamins Can Reduce Risk Of Low Birth Weight 2
... bench style refrigerator (can be situated on or ... of bags is to be stored as in ... white colorbond steel while the interior is a ... door is key lockable. Control panel is flush ...
The Testosterone Enzyme Immunoassay is intended for the quantitative determination of Testosterone concentration in human serum. No special pretreatment of the sample is necessary. For in vitro Diag...
DSL-10-49300 is a rapid, direct enzyme immunoassay (EIA) kit that provides materials for the quantitative measurement of testosterone in saliva. This assay requires no sample extraction or pretreat...
... This HPLC for Vitamin B6 makes ... an easy, fast and precise method. The ... form for preparation and separation of the ... of HPLC analytics is the simultaneous handling ...
Medicine Products: